Skip to main content
Clinical Trials/NCT06361667
NCT06361667
Completed
Not Applicable

"Culture and Well-being: Art as Prescription Therapy ("Art on Prescription"), Promoting Social Cohesion and Harnessing the "Silver Economy"

KAVADIA ELENI1 site in 1 country382 target enrollmentMarch 20, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Mental Health Issue
Sponsor
KAVADIA ELENI
Enrollment
382
Locations
1
Primary Endpoint
The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)
Status
Completed
Last Updated
7 months ago

Overview

Brief Summary

Stratified randomised controlled trial with two arms: arts intervention (any of the arts interventions, see list), which we call here Active Group (AG) vs waitlist control (WL).

Detailed Description

Design: Stratified randomised controlled trial with two arms: arts intervention (any of the arts interventions, see list), which we call here Active Group (AG) vs waitlist control (WL). Stratifying will happen at each site. Invastigators want to measure AG and WL, then WL becomes AG after 3 months and both the initial AG and the WL. AG will be measured in exactly the same way for another 3 months. AG for 3 months. Then goes into 3 month follow up. WL for 3 months. Then this group receives intervention and becomes AG and has measurements for 3 months as the AG did. There will be a 2-month break between T3 and T4 due to summer vacation. In the beginning, an open invitation to institutions of culture and mental health had been sent. Culture institutions i.e. Opera House, Contemporary Art Museum, National Theater etc. presented their action plans for interventional courses. Investigators did the connection between mental health and culture institutions. Potential participants declared their preference for the interventional course such as dance, cinema etc. and they listed while an external investigator did the blind randomization into AG or WL group. Frequency of Measurement: The primary outcome will be measured at time points (for adults): * T0: (before the randomisation; patient's personal data and demographics) * T1: (before the start of the intervention for the active group or the entry into the study for the WL group) * T2: 6 weeks (after the start of the intervention for the active group or the entry into the study for the WL group) * T3: 12 weeks (after the start of the intervention for the active group or the entry into the study for the WL group) The secondary outcomes will be measured at time points 0 (T4) and 12 weeks (T5) for both AG and WL. The primary outcome will be measured at time points (for children/adolescents): * T0: (before the randomisation; patient's personal data and demographics) * T1: (before the start of the intervention for the active group or the entry into the study for the WL group) * T3: 12 weeks (after the start of the intervention for the active group or the entry into the study for the WL group) The secondary outcomes will be measured at time points 0 (T4) and 12 weeks (T5) for both AG and WL.

Registry
clinicaltrials.gov
Start Date
March 20, 2024
End Date
December 19, 2024
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
KAVADIA ELENI
Responsible Party
Sponsor Investigator
Principal Investigator

KAVADIA ELENI

Executive Secretariat

University Mental Health Research Institute, Athens, Greece

Eligibility Criteria

Inclusion Criteria

  • age range: 10-99 years
  • be able to communicate effectively in order to provide answers to questionnaires that he/she will be asked to complete
  • be able to commit to monitoring the action
  • be able to participate in the activity alone (unaccompanied, without a carer),
  • be able to answer the questionnaires
  • to have legal capacity

Exclusion Criteria

  • active dependency,
  • patients that are not consistent in following pharmaceutical drugs,
  • patients from different Patient Association which is not "affiliated" with a Mental Health Professional Therapist.

Outcomes

Primary Outcomes

The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS)

Time Frame: 3 months

The Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS). This tool was developed in order to measure mental wellbeing in the general population by Tennant et al. (2007). It consists of 14 items responding using a 5-point Likert scale from 1 (never) to 5 (all the time). The overall score is calculated by summing the responses for every item without reversing none. The minimum overall score ranges from 14 to 70. Higher scores indicate increased mental wellbeing. The scale has been widely used nationally and internationally for monitoring, evaluating projects and programmes and investigating the determinants of mental wellbeing. An efficient internal consistency was proven using Cronbach's alpha score which was 0.89 for the student sample and 0.91 for the general population sample. Also, test-retest reliability at one week was high (0.83). The Greek validation showed acceptable internal consistency (Cronbach's alpha score 0.90).

The Patient Health Questionnaire-9 (PHQ-9)

Time Frame: 3 months

The Patient Health Questionnaire-9 (PHQ-9) is a questionnaire which measures depression and grade severity of symptoms in general medical and mental health settings using nine DSM-5 criteria for major depression within the last two weeks. PHQ-9 constructed by Kroenke et al. (2001) and validated in Greek by Hyphantis et al. (2011) is using a four-point Likert-type scale. After summing all responses (0=not at all, 3=nearly every day), scores range from 0 to 27, with higher levels indicating increased symptom severity (0-4 no to minimal; 5-9 mild; 10-14 moderate; 15-19 moderately severe; 20-27 severe). The internal reliability of the PHQ-9 was excellent, with a Cronbach's α of 0.89 in the PHQ Primary Care Study (Kroenke et al., 2001) and 0.82 in Greek validation (Hyphantis et al., 2011).

Generalised Anxiety Disorder Assessment (GAD-7)

Time Frame: 3 months

The Generalised Anxiety Disorder Assessment (GAD-7) is provided to screen symptom severity for the four most common anxiety disorders (generalized anxiety disorder, panic disorder, social phobia and posttraumatic stress disorder). GAD-7 constructed by Spitzer et al (2006) and validated in Greek by Vogazianos et al (2022). It consists of 7 items. The GAD-7 score is computed by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and summing together the scores for the seven questions (scores range from 0 to 21). Higher levels indicate increased anxiety. There are cut-offs for severity of anxiety as: (i) score 0-4: Minimal Anxiety; (ii) score 5-9: Mild Anxiety; (iii) score 10-14: Moderate Anxiety; (iv) score greater than 15: Severe Anxiety. The internal consistency of the GAD-7 was excellent (Cronbach α = 0.92) (Spitzer et al., 2006).

Secondary Outcomes

  • UCLA 3-item Loneliness Scale(3 months)
  • The Strengths and Difficulties Questionnaire (SDQ)(3 months)

Study Sites (1)

Loading locations...

Similar Trials